» Articles » PMID: 6590930

A Monoclonal Antibody Reactive with Normal and Leukemic Human Myeloid Progenitor Cells

Overview
Journal Leuk Res
Date 1984 Jan 1
PMID 6590930
Citations 73
Authors
Affiliations
Soon will be listed here.
Abstract

Anti-MY9 is an IgG2b murine monoclonal antibody selected for reactivity with immature normal human myeloid cells. The MY9 antigen is expressed by blasts, promyelocytes and myelocytes in the bone marrow, and by monocytes in the peripheral blood. Erythrocytes, lymphocytes and platelets are MY9 negative. All myeloid colony-forming cells (CFU-GM), a fraction of erythroid burst-forming cells (BFU-E) and multipotent progenitors (CFU-GEMM) are MY9 positive. This antigen is further expressed by the leukemic cells of a majority of patients with AML and myeloid CML-BC. Leukemic stem cells (leukemic colony-forming cells, L-CFC) from most patients tested were also MY9 positive. In contrast, MY9 was not detected on lymphocytic leukemias. Anti-MY9 may be a valuable reagent for the purification of hematopoietic colony-forming cells and for the diagnosis of myeloid-lineage leukemias.

Citing Articles

A framework integrating multiscale in-silico modeling and experimental data predicts CD33CAR-NK cytotoxicity across target cell types.

Ahmad S, Xing K, Rajakaruna H, Stewart W, Beckwith K, Nayak I bioRxiv. 2025; .

PMID: 39803543 PMC: 11722217. DOI: 10.1101/2024.12.31.630941.


CAR T-cell therapy in acute myeloid leukemia.

Almotiri A Saudi Med J. 2024; 45(10):1007-1019.

PMID: 39379118 PMC: 11463564. DOI: 10.15537/smj.2024.45.10.20240330.


Recent advances in CAR-T cell therapy for acute myeloid leukaemia.

Gao C, Li X, Xu Y, Zhang T, Zhu H, Yao D J Cell Mol Med. 2024; 28(9):e18369.

PMID: 38712978 PMC: 11075639. DOI: 10.1111/jcmm.18369.


Bispecific CD33/CD123 targeted chimeric antigen receptor T cells for the treatment of acute myeloid leukemia.

Boucher J, Shrestha B, Vishwasrao P, Leick M, Cervantes E, Ghafoor T Mol Ther Oncolytics. 2023; 31:100751.

PMID: 38075241 PMC: 10701585. DOI: 10.1016/j.omto.2023.100751.


A dual-receptor T-cell platform with Ab-TCR and costimulatory receptor achieves specificity and potency against AML.

Dao T, Xiong G, Mun S, Meyerberg J, Korontsvit T, Xiang J Blood. 2023; 143(6):507-521.

PMID: 38048594 PMC: 10950474. DOI: 10.1182/blood.2023021054.